Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

P. L. Zinzani, S. Sasse, J. Radford, O. Shonukan, V. Bonthapally

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Brentuximab vedotin was made available via a Named Patient Program (NPP) to non-US/Canadian patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL) until approval in their respective countries. We re-evaluated the efficacy and safety NPP data in a pooled analysis. Through a systematic literature review, 21 NPP publications were identified describing 14 cohorts (. N=. 245). Among patients with a specified diagnosis, 207 had HL, 28 had ALCL, and one had CD30+ T-cell lymphoma (not specified). In cohorts reporting response, overall response and complete remission rates were 67% and 26%, respectively, in R/R HL, and 75% and 74%, respectively, in R/R ALCL. Incidences of grade 3/4 neurologic and hematologic toxicities were 6% and 12%, respectively; 5% of patients discontinued because of toxicity. In real-world practice, response rates and tolerability to brentuximab vedotin are similar to those reported in the two pivotal phase 2 trials in these settings.

    Original languageEnglish
    Pages (from-to)359-369
    Number of pages11
    JournalCritical Reviews in Oncology/Hematology
    Volume95
    Issue number3
    DOIs
    Publication statusPublished - 1 Sept 2015

    Keywords

    • Anaplastic large cell lymphoma
    • Antibody-drug conjugate
    • Brentuximab vedotin
    • CD30
    • Hodgkin lymphoma
    • Named Patient Program

    Fingerprint

    Dive into the research topics of 'Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature'. Together they form a unique fingerprint.

    Cite this